Serum y-Neuropeptide Levels and Its Relationship with Body Fat Mass and Clinical Characteristics in Rheumatoid Arthritis

Melissa Ramirez-Villafaña¹, Paulina Hernandez-Cuervo², Ana Miriam Saldaña-Cruz³, Edsaul Emilio Perez-Guerrero^4,5, Nicte Selene Fajardo-Robledo⁶, Edy David Rubio-Arellano⁷, Alejandra Flores-Chavez⁸, Javier Alejandro Aceves-Aceves^9,10, Arnulfo Hernan Nava-Zavala¹¹, Mario Salazar-Paramo¹², Miguel Huerta¹³, Miriam Fabiola Alcaraz-Lopez¹⁴, Jorge Ivan Gamez-Nava¹⁵ and Laura Gonzalez-Lopez¹⁶, ¹Departamento Medicina Interna-Reumatología, Instituto Mexicano del Seguro Social, Hospital General Regional 110, Jalisco, Mexico, ²Programa de Doctorado en Ciencias de la Salud Pública, Centro Universitario de Ciencias de la Salud (CUCS), Universidad de Guadalajara. Guadalajara, Jalisco, México., Guadalajara, Mexico, ³Centro Universitario de Investigación Biomédica. Universidad de Colima, Colima, Mexico, ⁴Unidad de Investigación Biomédica 02 (Unidad de Investigación en Epidemiología Clínica), UMAE, Hospital de Especialidades Centro Médico Nacional de Occidente, Instituto Mexicano del Seguro Social, Jalisco, Mexico, ⁵Doctorado en Farmacología, Universidad de Guadalajara, Centro Universitario de Ciencias de la Salud, Jalisco, Mexico, ⁶Laboratorio de Investigación y Desarrollo Farmacéutico, Universidad de Guadalajara, Centro Universitario de Ciencias Exactas e Ingenierias, Jalisco, Mexico, ⁷Centro Universitario de Investigación Biomédica. Universidad de Colima., Colima, Colima, Mexico, ⁸Unidad de Investigación Biomédica 02 (Unidad de Investigación en Epidemiología Clínica), UMAE, Hospital de Especialidades, Centro Médico Nacional de Occidente, Instituto Mexicano del Seguro Social, Jalisco, Mexico, ⁹Departamento de Medicina Interna-Reumatologia, Hospital General Regional 110, IMSS, Guadalajara, Jalisco, Mexico, ¹⁰Posgrado de Farmacología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara., Guadalajara, Jalisco, Mexico, ¹¹Unidad de Investigación Biomédica 02 (Unidad de Investigación en Epidemiología Clínica), UMAE, Hospital de Especialidades Centro Médico Nacional de Occidente, IMSS, Jalisco, Mexico, ¹²Physiology, HSC, University of Guadalajara, Guadalajara, Mexico, ¹³Centro Universitario de Investigación Biomédica, Universidad de Colima, Colima, Mexico, ¹⁴Departamento Medicina Interna-Reumatología, Instituto Mexicano del Seguro Social, Hospital General Regional 45, Jalisco, Mexico, ¹⁵Rheumatology, Centro Medico de Occidente, Guadalajara Jal, Mexico, ¹⁶Departamento de Medicina Interna/Rheumatología, Hospital General Regional 110, Instituto Mexicano del Seguro Social (IMSS), Guadalajara, Jalisco, Mexico

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: arthritis and biomarkers, Disease Activity

Session Information

Date: Monday, November 14, 2016

Title: Rheumatoid Arthritis – Clinical Aspects - Poster II: Co-morbidities and Complications

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Overweight and obesity are comorbidities that may increase the risk of cardiovascular disease in rheumatoid arthritis. Increase in in body fat is observed in a high proportion of patients and increase of risk for cardiovascular diseases. Several biomarkers have been tested to be associated with cardiovascular risk. Neuropéptido-Y(NPY) is a neuroendocrine protein of anabolic signaling involved in the pathogenesis of increased body mass index and body fat mass, cardiovascular regulation and pro-inflammatory modulation. Currently, there is a lack of information regarding the clinical association of serum NPY levels in established RA. Objective:To evaluate the association between NPY levels with disease activity, body fat mass and risk factors for the development of cardiovascular disease in RA.

Methods: In this cross-sectional study, we evaluated 110 women with diagnosis of RA according to 1987 ACR criteria. We assessed disease activity by DAS-28. Percentage of fat mass was measured by dual X-ray absorptiometry (DXA) and cardiovascular risk factors using the Framingham index. Serum levels of NPY were measured by ELISA. Pearson’s test was used for the correlation between NPY with the variables of interest and multiple regression analysis in order to control for confounders

Results: The mean age was 58.5±11.2, mean disease duration 13.8±10.2, 97% of RA patients had high percentage of fat mass, and 62.7% had activity of their disease. In the correlation analysis we observed a negative correlation between NPY and body fat mass (r= -0.20, p=0.04) and a negative correlation with atherogenic index (r= -0.23, p=0.02); whereas, a positive correlation was observed between NPY with the TNF-alpha levels (r=0.52, p=0.005) and high-density lipoproteins (HDL-C) (r = 0.25, p <0.001); whereas, no correlation was observed between NPY and DAS-28, HAQ-DI or other variables. In the adjusted analysis after controlling by age, disease duration, fat mass, and other variables; the serum NPY levels were associated with increased in serum TNF-alpha levels (p=0.006); Glucocorticoids doses or use of biologic agents were not significant as confounders in the final model.

Conclusion: Serum levels of NPY are associated with lower percentage of body fat mass, lower score of atherogenic index and greater concentrations of TNF-alpha on RA. These interesting results encourage future longitudinal studies evaluating if changes of NPY levels during the disease may be associated with a modification of important outcomes mainly the development of future cardiovascular diseases in these patients.

Disclosure: M. Ramirez-Villafaña, None; P. Hernandez-Cuervo, None; A. M. Saldaña-Cruz, None; E. E. Perez-Guerrero, None; N. S. Fajardo-Robledo, None; E. D. Rubio-Arellano, None; A. Flores-Chavez, None; J. A. Aceves-Aceves, None; A. H. Nava-Zavala, None; M. Salazar-Paramo, None; M. Huerta, None; M. F. Alcaraz-Lopez, None; J. I. Gamez-Nava, None; L. Gonzalez-Lopez, None.

To cite this abstract in AMA style:

Ramirez-Villafaña M, Hernandez-Cuervo P, Saldaña-Cruz AM, Perez-Guerrero EE, Fajardo-Robledo NS, Rubio-Arellano ED, Flores-Chavez A, Aceves-Aceves JA, Nava-Zavala AH, Salazar-Paramo M, Huerta M, Alcaraz-Lopez MF, Gamez-Nava JI, Gonzalez-Lopez L. Serum y-Neuropeptide Levels and Its Relationship with Body Fat Mass and Clinical Characteristics in Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/serum-y-neuropeptide-levels-and-its-relationship-with-body-fat-mass-and-clinical-characteristics-in-rheumatoid-arthritis/. Accessed .

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/serum-y-neuropeptide-levels-and-its-relationship-with-body-fat-mass-and-clinical-characteristics-in-rheumatoid-arthritis/